Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2429 November 2025

APPLICAN	I <b>T</b> (stam	np or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:			First Names:	First Names:
Name:			Surname:	Surname:
Address:			DOB:	Address:
			Address:	
Fax Numbe				Fax Number:
Initial app	application ations only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months.  quisites(tick boxes where appropriate)  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has only received prior cytokine treatment  and The patient has an ECOG performance score of 0-2  and The patient has intermediate or poor prognosis defined as:  Lactate dehydrogenase level > 1.5 times upper limit of normal  or Haemoglobin level < lower limit of normal  or Corrected serum calcium level > 10 mg/dL (2.5 mmol/L)  or Karnofsky performance score of less than or equal to 70  The patient has intermediate or poor prognosis defined as:  Approvals valid for 3 months.  Approvals valid for 3 months.  Approvals valid for 3 months.  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell histology  The patient has metastatic renal cell carcinoma of predominantly clear cell			
or	L	Pazopanib to be used for a n	naximum of 3 months	
or	and and and	The patient has metastatic re The patient has discontinued The cancer did not progress Pazopanib to be used for a n	I sunitinib within 3 months of starting treatment due to whilst on sunitinib	o intolerance
Renewal  Current approval Number (if known):				

I confirm the above details are correct and that in signing this form I understand I may be audited.